Clik here to view.
Apricus Bio Seems Next To Follow In The Footsteps Of Threshold Pharma In SPA...
The following is a comparison of Apricus Bio, whom is awaiting FDA approval for Special Protocol Assessment on ProvOnco (liver cancer) during 1st quarter 2011 and Threshold Pharma, whom received this...
View ArticleClik here to view.
Optimer Nears First Blockbuster Treatment For $7B CDI Market In 25 Years
San Diego-based Optimer Pharmaceuticals has spent more than $200 million and a dozen years of effort to get to the point where it can ask the FDA to clear its first product for sale on the U.S. market....
View ArticleClik here to view.
Buyour Rumours For $19 A Share Swirling Around Optimer Pharma Ahead of PDUFA
Popularity in equities has never been higher than in 2011, with most analysts, including Hilary Kramer raving about the S&P 500 (NYSE:SPY) namely due to $2 trillion dollars worth of cash lying...
View ArticleClik here to view.
Medivation: The Most Promising Upcoming Prostate Cancer Treatment
Prostate cancer is the most common form of cancer among men, and two new companies in Medivation and Johnson & Johnson are leading the charge with their experimental new treatments. These two will...
View ArticleClik here to view.
Uncovering The Hidden Opportunity in Medivation’s Alzheimer’s Drug
Medivation (NADSAQ:MDVN) was once a thriving biotech with some of the most promising treatments for Alzheimer’s, Huntington Disease and Prostate cancer. Reaching an all-time high of $40 per share back...
View ArticleClik here to view.
Oxigene Nears Marketing Approval of First Anaplastic Thyroid Cancer Drug
With just a few weeks left on the calendar before the world’s largest oncology annual meeting, investors are already gearing up their portfolios for equities that could see exponential gains based on...
View ArticleClik here to view.
Atmel Looks To Continue Its Path Of Record Growth And Revenues
To many, Atmel remains an undiscovered secret within the technology sector, yet recent exclusive semiconductor manufacturing deals with the likes of Samsung, LG, Kyocera, Nokia, HTC, Hitachi, and...
View ArticleClik here to view.
Three Small Cap Biotechs Primed For Corrections Following ASCO
The month of May has thus far been a very profitable one for investors in a number of small cap biotechs leading up to the June 2011 ASCO meeting, particularly ones that haven’t consequently fared too...
View ArticleClik here to view.
Labeling and Script Use May Cause Problems For Optimer’s New Drug
Optimer Pharmaceuticals is quickly approaching its May 30th PDUFA as as heavy favourite to win a positive vote from the FDA to market its product, yet it seems that many investors are discounting the...
View ArticleClik here to view.
Bonds Nears Turning Point As Retail Investors Pile In
Shorting is a game that should be played with caution, however, if done at the right time can pay off handsomely. Generally, this is done when I see something that’s so drastically overvalued that I...
View Article
